Caribou Biosciences, Inc.
CRBU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.26 | -0.08 | 1.30 |
| FCF Yield | -100.77% | -24.80% | -25.51% | -3.92% |
| EV / EBITDA | -0.95 | -3.54 | -3.35 | -10.20 |
| Quality | ||||
| ROIC | -58.65% | -28.70% | -30.72% | -16.15% |
| Gross Margin | 60.71% | 89.78% | 73.71% | 89.75% |
| Cash Conversion Ratio | 0.93 | 0.91 | 0.91 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.31% | 53.15% | 3.87% | 18.36% |
| Free Cash Flow Growth | -37.94% | -7.68% | -173.34% | -3.21% |
| Safety | ||||
| Net Debt / EBITDA | -0.06 | 0.21 | 0.29 | 3.66 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -8,372.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -111.40 | -282.21 | 8.02 | -1,171.08 |